Clin Cancer Res: Long-term prognosis of rituximab+lenalidomide→lenalidomide in the treatment of indolent non-Hodgkin’s lymphoma

Rituximab and lenalidomide are effective against previously untreated relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL)

Lymphoma

Researchers such as Tuscano conducted two open-label phase II trials that included 60 previously untreated and R/R advanced iNHL patients

PFS and OS of patients in the untreated cohort (A) and R/R cohort (B)

PFS and OS of patients in the untreated cohort (A) and R/R cohort (B)

The median follow-up time of untreated advanced iNHL patients and R/R advanced iNHL patients was 63 months and 100 months, respectively; the ORR of both groups was 82%

The ORR of the two groups of patients was 82% .

Granzyme B ⁺ (GranB ⁺ ) of CD8 ⁺ there is a significant correlation between T cells and long-term complete remission (LTCR) between granzyme B ⁺ (GranB ⁺ ) of CD8 ⁺ presence of T cells and long-term complete remission (LTCR) between significant correlation ^{+ + + + +}

In summary, for previously untreated and R/R iNHL patients, rituximab combined with lenalidomide is effective for maintenance therapy with lenalidomide, and the toxicity is controllable

For previously untreated and R/R iNHL patients, rituximab combined with lenalidomide is effective for maintenance therapy with lenalidomide, and the toxicity is controllable for previously untreated and R/R iNHL patients , Rituximab combined with lenalidomide is effective for maintenance therapy with lenalidomide, and the toxicity is controllable ^{+ +}

Original source:

Original source:

Joseph M.

Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed / Refractory Indolent Lymphoma

in this message